These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3767313)

  • 1. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease.
    Beal MF; Mazurek MF; Chattha GK; Svendsen CN; Bird ED; Martin JB
    Ann Neurol; 1986 Sep; 20(3):282-8. PubMed ID: 3767313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease.
    Beal MF; Mazurek MF; Svendsen CN; Bird ED; Martin JB
    Ann Neurol; 1986 Oct; 20(4):489-95. PubMed ID: 3789664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex.
    Gabriel SM; Bierer LM; Harotunian V; Purohit DP; Perl DP; Davis KL
    Neurosci Lett; 1993 May; 155(1):116-20. PubMed ID: 8103205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease.
    Kowall NW; Beal MF
    Ann Neurol; 1988 Feb; 23(2):105-14. PubMed ID: 2897822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex.
    Beal MF; Mazurek MF
    Neurology; 1987 Jul; 37(7):1205-9. PubMed ID: 2439949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type.
    Dawbarn D; Rossor MN; Mountjoy CQ; Roth M; Emson PC
    Neurosci Lett; 1986 Sep; 70(1):154-9. PubMed ID: 2877420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease.
    Beal MF; Mazurek MF; Tran VT; Chattha G; Bird ED; Martin JB
    Science; 1985 Jul; 229(4710):289-91. PubMed ID: 2861661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin-28(1-12)-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex.
    Beal MF; Benoit R; Mazurek MF; Bird ED; Martin JB
    Brain Res; 1986 Mar; 368(2):380-3. PubMed ID: 2870772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease.
    Gabriel SM; Bierer LM; Davidson M; Purohit DP; Perl DP; Harotunian V
    J Neurochem; 1994 Apr; 62(4):1516-23. PubMed ID: 7510783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease.
    Beal MF; Mazurek MF; Ellison DW; Swartz KJ; McGarvey U; Bird ED; Martin JB
    Ann Neurol; 1988 Jun; 23(6):562-9. PubMed ID: 2900622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex.
    Beal MF; Clevens RA; Chattha GK; MacGarvey UM; Mazurek MF; Gabriel SM
    J Neurochem; 1988 Dec; 51(6):1935-41. PubMed ID: 2460590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease.
    Candy JM; Gascoigne AD; Biggins JA; Smith AI; Perry RH; Perry EK; McDermott JR; Edwardson JA
    J Neurol Sci; 1985 Dec; 71(2-3):315-23. PubMed ID: 2868073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex.
    Gabriel SM; Davidson M; Haroutunian V; Powchik P; Bierer LM; Purohit DP; Perl DP; Davis KL
    Biol Psychiatry; 1996 Jan; 39(2):82-91. PubMed ID: 8717605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma neuropeptide Y is reduced in patients with Alzheimer's disease.
    Koide S; Onishi H; Hashimoto H; Kai T; Yamagami S
    Neurosci Lett; 1995 Sep; 198(2):149-51. PubMed ID: 8592643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes.
    Beal MF; Clevens RA; Mazurek MF
    Synapse; 1988; 2(4):463-7. PubMed ID: 2903567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex.
    Mazurek MF; Beal MF
    Neurology; 1991 May; 41(5):716-9. PubMed ID: 1674117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The regional distribution of somatostatin and neuropeptide Y in control and Alzheimer's disease striatum.
    Beal MF; Mazurek MF; McKee MA
    Neurosci Lett; 1987 Aug; 79(1-2):201-6. PubMed ID: 2890123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: coexistence with neuropeptide Y neurons, and effects in Alzheimer-type dementia.
    Chan-Palay V
    J Comp Neurol; 1987 Jun; 260(2):201-23. PubMed ID: 2886516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system--I. Radioimmunoassay and chromatographic characterisation.
    de Quidt ME; Emson PC
    Neuroscience; 1986 Jul; 18(3):527-43. PubMed ID: 3755808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective lesion of the cholinergic basal forebrain causes a loss of cortical neuropeptide Y and somatostatin neurons.
    Zhang ZJ; Lappi DA; Wrenn CC; Milner TA; Wiley RG
    Brain Res; 1998 Aug; 800(2):198-206. PubMed ID: 9685641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.